Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

Atreya, Chintamani; Glynn, Simone; Busch, Michael; Kleinman, Steve; Snyder, Edward; Rutter, Sara; AuBuchon, James; Flegel, Willy; Reeve, David; Devine, Dana; Cohn, Claudia; Custer, Brian; Goodrich, Raymond; Benjamin, Richard J.; Razatos, Anna; Cancelas, Jose; Wagner, Stephen; Maclean, Michelle; Gelderman, Monique; Cap, Andrew; Ness, Paul

There are still unknowns with respect to the use of PItreated PLTs in actively bleeding patients, particularly those with massive hemorrhage. 55 Whether use of large volumes of PI-treated products, including PI-treated PLTs will amplify the negative effect of PI on PLT efficacy and overall hemostasis remains to be determined. Limited retrospective studies in surgical patients have not given cause for alarm with respect to adverse reactions or efficacy. 32, 93 Important research questions remain to be answered: 1) Can we develop strategies to minimize damage to PLTs and RBCs including the use of better ASs and storage conditions ‡ Retention rate of platelets after the PRT process (mean AE standard deviation; number of PRT platelet products tested for quality assurance to document the loss of platelets) n/a − not applicable.